IP Library › Granted Patent US 12,252,682
Granted Patent B2
US 12,252,682 · App. 17/734,562 · Granted Mar 18, 2025

System and method for fluid flow management in a bioprocessing system

Inventors: Weston Blaine Griffin (Niskayuna, NY); Alex D Corwin (Niskayuna, NY); Xiaohua Zhang (Niskayuna, NY); Reginald Donovan Smith (Niskayuna, NY); Zhen Liu (Niskayuna, NY); Chengkun Zhang (Niskayuna, NY); Vandana Keskar (Niskayuna, NY); Brian Michael Davis (Niskayuna, NY); Kashan Shaikh (Niskayuna, NY)
Assignee: GLOBAL LIFE SCIENCES SOLUTIONS USA LLC
C12M41/44C12M23/58C12M29/00C12M33/14
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,252,682
App. No.
17/734,562
Granted
Mar 18, 2025
Kind
B2
Abstract

A bioprocessing system includes a first fluid assembly having a first fluid assembly line connected to a first port of a first bioreactor vessel though a first bioreactor line of a first bioreactor vessel, a second fluid assembly having a second fluid assembly line connected to a second port of the first bioreactor vessel through a second bioreactor line of the first bioreactor vessel, and an interconnect line providing for fluid communication between the first fluid assembly and the second fluid assembly, and for fluid communication between the second bioreactor line of the first bioreactor vessel and the first bioreactor line of the first bioreactor vessel.

Claims (64)

1. A bioprocessing system, comprising:

a first fluid assembly configured for connection to one or more sources of fluid for input into the bioprocessing system, the first fluid assembly having a first fluid assembly line connected to a first port of a first bioreactor vessel though a first bioreactor line of the first bioreactor vessel, the first bioreactor line of the first bioreactor vessel including a first bioreactor line valve for providing selective fluid communication between the first fluid assembly and the first port of the first bioreactor vessel;

a second fluid assembly having a second fluid assembly line connected to a second port of the first bioreactor vessel through a second bioreactor line of the first bioreactor vessel, the second bioreactor line of the first bioreactor vessel including a second bioreactor line valve for providing selective fluid communication between the second fluid assembly and the second port of the first bioreactor vessel;

an interconnect line providing for fluid communication between the first fluid assembly and the second fluid assembly, and for fluid communication between the second bioreactor line of the first bioreactor vessel and the first bioreactor line of the first bioreactor vessel; and

a sampling assembly connected to at least one of the first fluid assembly, the second fluid assembly, the interconnect line and/or a fluid flowpath intermediate the second bioreactor line valve and the first bioreactor line valve, the sampling assembly including a sampling assembly line providing for fluid communication between the sampling assembly and the second port of the first bioreactor vessel;

wherein the sampling assembly is connected to the interconnect line intermediate the second bioreactor line valve and the first bioreactor line valve.

2. The bioprocessing system of claim 1 , wherein:

the first fluid assembly comprises a plurality tubing tails, each tubing tail of the first fluid assembly being configured for connection to one of a plurality of first reservoirs; and

the second fluid assembly includes a plurality tubing tails, each tubing tail of the second fluid assembly being configured for connection to one of a plurality of second reservoirs.

3. The bioprocessing system of claim 2 , wherein:

each tubing tail of the first fluid assembly includes a tubing tail valve for controlling a flow of fluid to or from a respective one of the plurality of first reservoirs; and

each tubing tail of the second fluid assembly includes a tubing tail valve for controlling a flow of fluid to or from a respective one of the plurality of second reservoirs.

4. The bioprocessing assembly of claim 1 , wherein:

the sampling assembly includes at least one tubing tail configuration for connection to a sampling terminus.

5. The bioprocessing system of claim 1 , further comprising:

a sterile air source line connected to at least one of the first fluid assembly, the second fluid assembly, the interconnect line and/or the fluid flowpath intermediate the second bioreactor line valve and the first bioreactor line valve, the sterile air source line including a sterile air source line valve for selectively controlling a flow of sterile air from a sterile air source to at least one of the first fluid assembly, the second fluid assembly and/or the interconnect line.

6. The bioprocessing system of claim 1 , wherein:

the interconnect line includes an interconnect line valve for providing selective fluid communication between at least the first fluid assembly and the second fluid assembly.

7. The bioprocessing system of claim 1 , wherein:

the second fluid assembly is configured to receive fluid from at least one of the first fluid assembly and/or the first bioreactor vessel.

8. The bioprocessing system of claim 1 , wherein:

the second fluid assembly includes at least one of a waste reservoir for receiving waste and/or a collection container for receiving an expanded population of cells.

9. A bioprocessing system, comprising:

a first fluid assembly configured for connection to one or more sources of fluid for input into the bioprocessing system, the first fluid assembly having a first fluid assembly line connected to a first port of a first bioreactor vessel though a first bioreactor line of the first bioreactor vessel, the first bioreactor line of the first bioreactor vessel including a first bioreactor line valve for providing selective fluid communication between the first fluid assembly and the first port of the first bioreactor vessel;

a second fluid assembly having a second fluid assembly line connected to a second port of the first bioreactor vessel through a second bioreactor line of the first bioreactor vessel, the second bioreactor line of the first bioreactor vessel including a second bioreactor line valve for providing selective fluid communication between the second fluid assembly and the second port of the first bioreactor vessel;

an interconnect line providing for fluid communication between the first fluid assembly and the second fluid assembly, and for fluid communication between the second bioreactor line of the first bioreactor vessel and the first bioreactor line of the first bioreactor vessel;

a bidirectional first pump located along the first fluid assembly line and configured to initiate a flow of fluid between the first fluid assembly and the first bioreactor vessel, and between the first fluid assembly and the second fluid assembly; and

a bidirectional second pump configured to initiate a flow of fluid between the second fluid assembly and the first bioreactor vessel.

10. The bioreactor system of claim 9 , wherein:

the bidirectional second pump is configured to initiate a flow of fluid between the first bioreactor vessel and a second bioreactor vessel.

11. A bioprocessing system, comprising:

a first fluid assembly configured for connection to one or more sources of fluid for input into the bioprocessing system, the first fluid assembly having a first fluid assembly line connected to a first port of a first bioreactor vessel though a first bioreactor line of the first bioreactor vessel, the first bioreactor line of the first bioreactor vessel including a first bioreactor line valve for providing selective fluid communication between the first fluid assembly and the first port of the first bioreactor vessel;

a second fluid assembly having a second fluid assembly line connected to a second port of the first bioreactor vessel through a second bioreactor line of the first bioreactor vessel, the second bioreactor line of the first bioreactor vessel including a second bioreactor line valve for providing selective fluid communication between the second fluid assembly and the second port of the first bioreactor vessel;

an interconnect line providing for fluid communication between the first fluid assembly and the second fluid assembly, and for fluid communication between the second bioreactor line of the first bioreactor vessel and the first bioreactor line of the first bioreactor vessel;

a filtration line in fluid communication with the interconnect line and the first bioreactor line of the first bioreactor vessel; and

a filter positioned along the filtration line;

wherein the interconnect line is connected to the second bioreactor line of the first bioreactor vessel, and the first bioreactor line and the first fluid assembly line;

wherein the interconnect line includes an interconnect line valve for providing selective fluid communication between at least the first fluid assembly and the second fluid assembly; and

wherein the filtration line surrounds the interconnect line valve of the interconnect line so that a flow of fluid through the interconnect line can be forced through the filtration line.

12. The bioprocessing system of claim 11 , further comprising:

a permeate waste line providing fluid communication between the filter and a waste reservoir connected to the second fluid assembly for conveying waste removed from the fluid to the waste reservoir.

13. The bioprocessing system of claim 12 , further comprising:

a permeate waste pump configured to pump the waste from the filter to the waste reservoir.

14. The bioprocessing system of claim 11 , wherein:

the filter is one of a hollow fiber filter and a flat sheet membrane.

15. A bioprocessing system, comprising:

a first fluid assembly configured for connection to one or more sources of fluid for input into the bioprocessing system, the first fluid assembly having a first fluid assembly line connected to a first port of a first bioreactor vessel though a first bioreactor line of the first bioreactor vessel, the first bioreactor line of the first bioreactor vessel including a first bioreactor line valve for providing selective fluid communication between the first fluid assembly and the first port of the first bioreactor vessel;

a second fluid assembly having a second fluid assembly line connected to a second port of the first bioreactor vessel through a second bioreactor line of the first bioreactor vessel, the second bioreactor line of the first bioreactor vessel including a second bioreactor line valve for providing selective fluid communication between the second fluid assembly and the second port of the first bioreactor vessel; and

an interconnect line providing for fluid communication between the first fluid assembly and the second fluid assembly, and for fluid communication between the second bioreactor line of the first bioreactor vessel and the first bioreactor line of the first bioreactor vessel;

wherein the first fluid assembly line of the first fluid assembly is further connected to a first port of a second bioreactor vessel through a first bioreactor line of the second bioreactor vessel, the first bioreactor line of the second bioreactor vessel including a first bioreactor line valve for providing selective fluid communication between the first fluid assembly and the first port of the second bioreactor vessel; and

wherein the second fluid assembly line of the second fluid assembly is connected to a second port of the second bioreactor vessel through a second bioreactor line of the second bioreactor vessel, the second bioreactor line of the second bioreactor vessel include a second bioreactor line valve for providing selective fluid communication between the second fluid assembly and the second port of the second bioreactor vessel.

16. The bioprocessing system of claim 15 , wherein:

the interconnect line provides for fluid communication between the second bioreactor line of the second bioreactor vessel and the first bioreactor line of the second bioreactor vessel.

17. The bioprocessing system of claim 16 , wherein:

the interconnect line provides for fluid communication between the second bioreactor line of the second bioreactor vessel and the second fluid assembly.

18. A bioprocessing system, comprising:

a first fluid assembly configured for connection to one or more sources of fluid for input into the bioprocessing system, the first fluid assembly having a first fluid assembly line connected to a first bioreactor vessel though a first bioreactor line of the first bioreactor vessel;

a second fluid assembly having a second fluid assembly line connected to the first bioreactor vessel through a second bioreactor line of the first bioreactor vessel;

an interconnect line providing for fluid communication between the first fluid assembly and the second fluid assembly, and for fluid communication between the second bioreactor line of the first bioreactor vessel and the first bioreactor line of the first bioreactor vessel;

a bidirectional first pump located along the first fluid assembly line and configured to initiate a flow of fluid between the first fluid assembly and the first bioreactor vessel, and between the first fluid assembly and the second fluid assembly; and

a bidirectional second pump configured to initiate a flow of fluid between the second fluid assembly and the first bioreactor vessel.

19. The bioprocessing system of claim 18 , wherein:

the first bioreactor line of the first bioreactor vessel includes a first bioreactor line valve for providing selective fluid communication between the first fluid assembly and a first port of the first bioreactor vessel; and

wherein the second bioreactor line of the first bioreactor vessel includes a second bioreactor line valve for providing selective fluid communication between the second fluid assembly and a second port of the first bioreactor vessel.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 3, 2022
From: GRIFFIN, WESTON BLAINE; CORWIN, ALEX D; ZHANG, XIAOHUA; SMITH, REGINALD DONOVAN; LIU, ZHEN; ZHANG, CHENGKUN; KESKAR, VANDANA; DAVIS, BRIAN MICHAEL; SHAIKH, KASHAN
To: GENERAL ELECTRIC COMPANY
Reel/Frame 059796/0301 →
CHANGE OF NAME Recorded May 3, 2022
From: GENERAL ELECTRIC COMPANY
To: GLOBAL LIFE SCIENCES SOLUTIONS USA LLC
Reel/Frame 059848/0001 →
Continuity (10)
Continuation 16968391
Continuation In Part 15893336 · Feb 9, 2018
Provisional Application 62736115 · Sep 25, 2018
Provisional Application 62736130 · Sep 25, 2018
Provisional Application 62736125 · Sep 25, 2018
Provisional Application 62736144 · Sep 25, 2018
Provisional Application 62736154 · Sep 25, 2018
Provisional Application 62736120 · Sep 25, 2018
Provisional Application 62736143 · Sep 25, 2018
Related Publication 20220251496A1 · Aug 11, 2022
References Cited (158)
US 4143764A · Moss, III · 1979 [cited by applicant]
US 5117870A · Goodale et al. · 1992 [cited by applicant]
US 5449617A · Falkenberg et al. · 1995 [cited by applicant]
US 5506117A · Andrews et al. · 1996 [cited by applicant]
US 5693537A · Wilson et al. · 1997 [cited by applicant]
US 5985153A · Dolan et al. · 1999 [cited by applicant]
US 7601545B2 · Barringer, Jr. · 2009 [cited by applicant]
US 7745209B2 · Martin · 2010 [cited by applicant]
US 8158427B2 · Wilson · 2012 [cited by applicant]
US 9175253B2 · Hata et al. · 2015 [cited by applicant]
US 9206383B2 · Vunjak-Novakovic et al. · 2015 [cited by applicant]
US 10131876B2 · Kaiser et al. · 2018 [cited by applicant]
US 10350245B2 · Adair et al. · 2019 [cited by applicant]
US 11236298B2 · Stone et al. · 2022 [cited by applicant]
US 20020055166A1 · Cannon et al. · 2002 [cited by applicant]
US 20020189374A1 · Desilets et al. · 2002 [cited by applicant]
US 20040214314A1 · Srienc et al. · 2004 [cited by applicant]
US 20050051723A1 · Neagle et al. · 2005 [cited by applicant]
US 20080213894A1 · Antwiler · 2008 [cited by applicant]
US 20080227190A1 · Antwiler · 2008 [cited by applicant]
US 20090037031A1 · George et al. · 2009 [cited by applicant]
US 20090286315A1 · Pattou et al. · 2009 [cited by applicant]
US 20100144037A1 · Antiwiler · 2010 [cited by applicant]
US 20100236340A1 · Lee · 2010 [cited by examiner]
US 20100291534A1 · Higuchi et al. · 2010 [cited by applicant]
US 20110136225A1 · Vunjak-Novakovic et al. · 2011 [cited by applicant]
US 20120149021A1 · Yung et al. · 2012 [cited by applicant]
US 20130157353A1 · Dijkuizen Borgart et al. · 2013 [cited by applicant]
US 20140335608A1 · Tanaka · 2014 [cited by examiner]
US 20150072401A1 · Nozaki et al. · 2015 [cited by applicant]
US 20150090664A1 · Nokleby et al. · 2015 [cited by applicant]
US 20150158907A1 · Zhou et al. · 2015 [cited by applicant]
US 20150166945A1 · Andersen et al. · 2015 [cited by applicant]
US 20150299644A1 · Tijsterman · 2015 [cited by applicant]
US 20150344833A1 · Kimura et al. · 2015 [cited by applicant]
US 20160123848A1 · Griffin et al. · 2016 [cited by applicant]
US 20160215257A1 · Davis et al. · 2016 [cited by applicant]
US 20160340633A1 · Davis et al. · 2016 [cited by applicant]
US 20160355777A1 · Fachin et al. · 2016 [cited by applicant]
US 20170253847A1 · Koseki · 2017 [cited by examiner]
US 20180066248A1 · Kusner · 2018 [cited by applicant]
US 20190388855A1 · Ramakrishna et al. · 2019 [cited by applicant]
CN 102504991 · 2012 [cited by applicant]
CN 104640973 · 2015 [cited by applicant]
CN 105392877 · 2016 [cited by applicant]
CN 106062185A · 2016 [cited by applicant]
EP 0950432 · 1999 [cited by applicant]
EP 1944359 · 2008 [cited by applicant]
EP 2589652 · 2013 [cited by applicant]
GB 2268187 · 1994 [cited by applicant]
JP 57100900 · 1982 [cited by applicant]
JP 10504710 · 1998 [cited by applicant]
JP 2002542004 · 2002 [cited by applicant]
JP 2003504195 · 2003 [cited by applicant]
JP 2006149232 · 2006 [cited by applicant]
JP 2009514796 · 2009 [cited by applicant]
JP 2009502183 · 2009 [cited by applicant]
JP 2012506706 · 2012 [cited by applicant]
JP 2013223820 · 2013 [cited by applicant]
JP 2013539356 · 2013 [cited by applicant]
JP 2015518734 · 2015 [cited by applicant]
JP 2015188391 · 2015 [cited by applicant]
JP 2015221001A · 2015 [cited by applicant]
JP 2015221002 · 2015 [cited by applicant]
JP 2015223169 · 2015 [cited by applicant]
JP 2017528121 · 2016 [cited by applicant]
JP 2016059316 · 2016 [cited by applicant]
JP 2016153124 · 2016 [cited by applicant]
JP 2016530893 · 2016 [cited by applicant]
JP 201760534 · 2017 [cited by applicant]
JP 201785899 · 2017 [cited by applicant]
JP 2017513499 · 2017 [cited by applicant]
KR 1020080072006A · 2008 [cited by applicant]
KR 20080072006 · 2008 [cited by applicant]
KR 20160055866 · 2016 [cited by applicant]
KR 1020160145162A · 2016 [cited by applicant]
KR 20160145162 · 2016 [cited by applicant]
RU 2373273 · 2009 [cited by applicant]
WO 9724144 · 1997 [cited by applicant]
WO 0228996 · 2002 [cited by applicant]
WO 02102965 · 2002 [cited by applicant]
WO 2003087292 · 2003 [cited by applicant]
WO 2005009126 · 2005 [cited by applicant]
WO 2007052718 · 2007 [cited by applicant]
WO 2008109200 · 2008 [cited by applicant]
WO 2009112952 · 2009 [cited by applicant]
WO 2010062599 · 2010 [cited by applicant]
WO 2010080032 · 2010 [cited by applicant]
WO 2010080032A2 · 2010 [cited by applicant]
WO 2012127523 · 2012 [cited by applicant]
WO 2013114845 · 2013 [cited by applicant]
WO 2014033889 · 2014 [cited by applicant]
WO 2015042450 · 2015 [cited by applicant]
WO 2015056302 · 2015 [cited by applicant]
WO 2016100227 · 2016 [cited by applicant]
WO 2016107788 · 2016 [cited by applicant]
WO 2016113369 · 2016 [cited by applicant]
WO 2016118780 · 2016 [cited by applicant]
WO 2016161174 · 2016 [cited by applicant]
WO 2016168687 · 2016 [cited by applicant]
WO 2016170623 · 2016 [cited by applicant]
WO 2016185221 · 2016 [cited by applicant]
WO 2016185221A1 · 2016 [cited by applicant]
WO 2016189159A1 · 2016 [cited by applicant]
WO 2015087369 · 2017 [cited by applicant]
WO 2017032829 · 2017 [cited by applicant]
WO 2017035262 · 2017 [cited by applicant]
WO 2017038887 · 2017 [cited by applicant]
WO 2017109083 · 2017 [cited by applicant]
WO 2017221155 · 2017 [cited by applicant]
WO 2018005521 · 2018 [cited by applicant]
WO 2018122192 · 2018 [cited by applicant]
WO 2019046766 · 2019 [cited by applicant]
English translation of Chinese Office Action dated Aug. 31, 2023 for Application No. 201980024224.7. [cited by applicant]
English translation of Chinese Office Action dated Aug. 16, 2023 for Application No. 201980024223.2. [cited by applicant]
English translation of Chinese Office Action dated Aug. 30, 2023 for Application No. 201980024235.5. [cited by applicant]
English translation of Chinese Office Action dated Aug. 31, 2023 for Application No. 201980024222.8 .. [cited by applicant]
United States Office Action for U.S. Appl. No. 16/968,342 dated Apr. 6, 2023. [cited by applicant]
United States Office Action for U.S. Appl. No. 17/078,157 dated Apr. 14, 2023. [cited by applicant]
English translation of Korean Office Action dated Sep. 19, 2023 for Application No. 10-2020-7025576. [cited by applicant]
English translation of Korean Office Action dated Sep. 19, 2023 for Application No. 10-2020-7025586. [cited by applicant]
English translation of Korean Office Action dated Sep. 19, 2023 for Application No. 10-2020-7025562. [cited by applicant]
English translation of Russian Search Report dated Jun. 28, 2022 for corresponding Application No. PCT/EP2019/053205 filed Aug. 2, 2019. [cited by applicant]
English translation of Russian Office Action dated Jun. 28, 2022 for corresponding Application No. PCT/EP2019/053205 filed Aug. 2, 2019. [cited by applicant]
Indian Office Action dated Jul. 8, 2022 from corresponding Indian Application No. 202017032170 filed Jul. 27, 2020. [cited by applicant]
United States Office Action dated Apr. 15, 2022 from corresponding U.S. Appl. No. 16/968,331, filed Aug. 7, 2020. [cited by applicant]
English translation of Japanese Office Action dated Jan. 26, 2023 from corresponding Japanese Application No. 2020-542891. [cited by applicant]
English translation of Japanese Office Action dated Sep. 12, 2022 from corresponding Japanese Application No. 2020-529614. [cited by applicant]
English translation of Chinese Office Action dated Sep. 5, 2022 from corresponding Chinese Application No. 202080010621.1. [cited by applicant]
Cyrille J. Cohen, et al., Recognition of Fresh Human Tumor by Human Peripheral Blood Lymphocytes Transduced with a Bicistronic Retroviral Vector Encoding a Murine Anti-p53 TCR; J Immunol. Nov. 1, 2005; 175 (9): 5799-580… [cited by applicant]
P. Neeson, et al., Ex vivo culture of chimeric antigen receptor T cells generates functional CD8+ T cells with effector and central memory-like phenotype; Gene Therapy (2010) 17, pp. 1105-1116. [cited by applicant]
Barbara Savoldo, et al., CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients; The Journal of Clinical Investigation; vol. 121; No. 5; May 2011; pp. 18… [cited by applicant]
Ryan D. Guest, et al., Definition and application of good manufacturing process-compliant production of CEA-specific chimeric antigen receptor expressing T-cells for phase I/II clinical trial; Cancer Immunol Immunother … [cited by applicant]
Anna Casati,, et al., Clinical-scale selection and viral transduction of human naive and central memory CD8+ T cells for adoptive cell therapy of cancer patients; Cancer Immunol Immunother. Oct. 2013; 62(10): 1563-1573,… [cited by applicant]
Antonio Di Stasi, et al., T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model; The American Society of Hematology; Blood Ju… [cited by applicant]
Katsuyuki Dodo, et al., An Efficient Large-Scale Retroviral Transduction Method Involving Preloading the Vector into a RetroNectin-Coated Bag with Low-Temperature Shaking; PLOS One; Jan. 2014, vol. 9, Issue 1, pp. 1-12. [cited by applicant]
I.A. Hedfors, et al., Long-Term Proliferation and Survival of In Vitro-Activated T Cells is Dependent on Interleukin-2 Receptor Signalling but not on the High-Affinity IL-2R; 2003 Blackwell Publishing Ltd. Scandinavian … [cited by applicant]
Daniel Hollyman, et al., Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy; J Immunother. 2009; 32(2): 169-180; pp. 1-22. [cited by applicant]
Laura A. Johnson, et al., Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen; Blood, Jul. 16, 2009, vol. 114, No. 3, pp. 535-546. [cited by applicant]
Ad Kaiser, et al., Towards a commercial process for the manufacture of genetically modified T cells for therapy; Nature America, Inc; Cancer Gene Therapy (2015) 22, pp. 72-78. [cited by applicant]
Robert PT Somerville, et al., Clinical scale rapid expansion of lymphocytes for adoptive cell transfer therapy in the WAVE bioreactor; Journal of Translational Medicine 2012, 10:69; pp. 1-11. [cited by applicant]
Barbara Tumaini, et al., Simplified process for the production of anti-CD19-CAR engineered T cells; Cytotherapy. Nov. 2013 ; 15(11): 1406-1415; pp. 1-19. [cited by applicant]
Paul C. Tumeh, et al, The impact of ex vivo clinical grade activation protocols on human T cell phenotype and function for the generation of genetically modified cells for adoptive cell transfer therapy; Immunother. Oct… [cited by applicant]
David Porter, et al., Pilot Study of Redirected Autologous T Cells Engineered to Contain ANTI-CD19 Attached to TCR and 4-1BB Signaling Domains in Patients With Chemotherapy Resistance or Refractory CD19+ Leukemia and Ly… [cited by applicant]
SS Yu, et al., In vivo persistence of genetically modified T cells generated ex vivo using the fibronectin CH296 stimulation method; Nature Publishing Group; Cancer Gene Therapy (2008) 15, pp. 508-516. [cited by applicant]
English translation of Japanese Office Action dated Jan. 10, 2023 from corresponding Japanese Application No. 2020-542856. [cited by applicant]
English translation of Japanese Office Action dated Jan. 10, 2023 from corresponding Japanese Application 2020-542889. [cited by applicant]
English translation of Japanese Office Action dated Jan. 10, 2023 from corresponding Japanese Application 2020-542847. [cited by applicant]
English translation of Japanese Office Action dated Dec. 23, 2022 from corresponding Japanese Application 2020-542846. [cited by applicant]
English translation of Japanese Office Action dated Jan. 4, 2023 from corresponding Japanese Application 2020-542890. [cited by applicant]
Australian Examination Report dated Nov. 30, 2023 for Application No. 2019219295. [cited by applicant]
English translation of Chinese Office Action dated Dec. 21, 2023 for Application No. 201880088322.2. [cited by applicant]
Corresponding Korean Patent Application No. 10-2020-7025578 Office Action dated May 23, 2024. [cited by applicant]
Corresponding Chinese Patent Application No. 201980024222.8 Office Action dated May 29, 2024. [cited by applicant]
Hollyman, Daniel; Title: Manufacturing validation of biologically functional T Cells targeted to CD19 antigen for autologous adoptive cell therapy; Date: Feb. 1, 2010. [cited by applicant]
United States Office Action dated Oct. 30, 2024 for U.S. Appl. No. 16/968,374. [cited by applicant]
Mock et al. Automated manufacturing of chimeric antigen receptor T cells for adoptive immunotherapy using CliniMACS Prodigy Cytotherapy, 2016; 18: 1002-1011. (Year 2016). [cited by applicant]
GE Application note. “Perfucsion culture of T lymphocytes in the WAVE Bioreactor System 2/10 (software version 2.61)”, GE Healthcare Life Sciences, Application note 28-9650-52 AC. Published Jan. 2010, p. 1-9. (Year: 201… [cited by applicant]